13 Impairment of non-financial assets

13 Impairment of non-financial assets

A review of the recoverable amounts of the Group’s assets resulted in the recognition of impairment charges amounting to € 2 million (2018: € 0 million), relating to the micro RNA targeting platform acquired from Beryllium LLC.

No impairment charges for Group property, plant and equipment were recognized in 2019 (2018: € 0 million).

No reasonably possible change in a key assumption on which management has based its determination of the assets recoverable amounts would cause the assets carrying amount to exceed its recoverable amount.